Biotech survey sees tough days ahead. Plus: Makary’s FDA vision, China’s speed trials

On the latest BioCentury This Week podcast, the results of BioCentury’s Risk Sentiment survey

The biotech community is reeling, fearful and furious about the fallout of tariff, FDA and NIH policies, according to BioCentury’s newly released Risk Sentiment survey, with access to capital top of mind. On the latest BioCentury This Week podcast, BioCentury’s editors discuss takeaways from the survey, which polled 328 biopharma stakeholders during April 10-14.

The editors then dissect the latest from Washington, including comments from FDA Commissioner Marty Makary on a new pathway for ultrarare drugs and his plans to reform advisory committee meetings, as well as last week’s executive order on drug pricing. They also discuss how China’s biotechs may have cracked one of the key bottlenecks for both speeding up and de-risking early drug development — and what this means for U.S. biotech.

This episode of BioCentury This Week podcast is sponsored by RemeGen.